UK regulatory landscape
Tirzepatide (Mounjaro) in the UK: dispensing landscape
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-20
Tirzepatide, marketed in the UK as Mounjaro, is a prescription-only medicine (POM) regulated by the MHRA. We publish this page as a regulatory and dispensing-landscape reference, not a recommendation. Your UK-licensed prescriber decides whether tirzepatide is appropriate for you, based on the SmPC, the PIL, and your individual clinical picture. This is editorial commentary on the framework that exists in 2026: the MHRA marketing authorisation, the NICE TA1026 pathway, the NHS England phasing, and the legitimate UK dispensing routes (NHS, private clinic, community pharmacy).
NHS pathway
NHS England access
NICE TA1026 sets the clinical eligibility cohorts. Cohort 1 has been in active rollout since June 2025 (BMI 40+ with four or more weight-related comorbidities). Cohort 2 commenced 23 June 2026 (BMI 35+). Cohort 3 is signalled for April 2027. Access is via specialist weight management services in line with ICB commissioning.
Read the NHS access editorial →
Private route
CQC-registered clinics
Independent CQC-registered providers in the UK that include tirzepatide on their formulary include Numan, Voy, Manual, and Juniper. These are app-based programmes coupling a prescriber consultation with ongoing clinical review. Whether this pathway is appropriate is a decision for your prescriber.
UK regulated clinic directory →
Pharmacy route
GPhC-registered pharmacies
UK pharmacies registered with the General Pharmaceutical Council that dispense tirzepatide after an online prescriber consultation include Phlo, Pharmacy2U, SimplyMeds, and Boots Online Doctor. Dispensing is contingent on a valid UK prescription issued by a registered prescriber.
UK regulated pharmacy directory →
Regulatory points worth knowing
- · Tirzepatide is POM throughout the UK. Supply outside a valid prescription issued by a UK-registered prescriber is unlawful under the Human Medicines Regulations 2012.
- · The MHRA has stated public enforcement activity against grey-import and unlicensed-supply channels, including significant seizures of trafficked weight-management medicines in early 2026. Falsified medicines do not have the assurance of the UK regulated supply chain.
- · The MHRA-approved SmPC lists pregnancy and breastfeeding among the contraindications. Suitability in any individual is a matter for the prescriber, referencing the SmPC and the PIL.
Further editorial: NHS access pathway · aftercare reference.
Important: POM, your UK-licensed prescriber decides
Tirzepatide (Mounjaro) is a prescription-only medicine. PeptideClear is an editorial publication, not a pharmacy, not a clinic, and not a prescriber. We do not sell, dispense, or recommend tirzepatide for any individual. We publish this page as a UK regulatory and dispensing-landscape reference. Your UK-licensed prescriber, working from the MHRA-approved SmPC, the PIL, NICE TA1026, and your clinical picture, decides whether tirzepatide is appropriate for you.